Youth-onset type 2 diabetes in Israel: A national cohort.

David Strich, Naim Shehadeh, Orit Pinhas-Hamiel, Yael Lebenthal, Ram Weiss, Rami Tibi, Floris Levy-Khademi, Tal Ben-Ari, Marianna Rachmiel, Yossi Schon, Yonatan Yeshayahu, Avivit Brener, Nehama Zuckerman Levin, David Zangen, Kineret Mazor Aronovitch, Alon Haim, Eli Hershkovitz, Osnat Admoni, Yardena Tenenbaum-Rakover, Ilana Koren, Ariel Tenenbaum, Moshe Phillip, Meidan Cohen

Journal: Pediatric diabetes 2022;23(6):649-659

PMID: 35521999

Abstract

BACKGROUND

Prevalence of youth-onset type 2 diabetes (T2D) has increased worldwide, paralleling the rise in pediatric obesity. Occurrence and clinical manifestations vary regionally and demographically.

OBJECTIVES

We assessed the incidence, and clinical and demographic manifestations of youth-onset T2D in Israel.

METHODS

In a national observational study, demographic, clinical, and laboratory data were collected from the medical records of children and adolescents, aged 10-18 years, diagnosed with T2D between the years 2008 and 2019.

RESULTS

The incidence of youth-onset T2D in Israel increased significantly from 0.63/100,000 in 2008 to 3.41/100,000 in 2019. The study cohort comprised 379 individuals (228 girls [59.7%], 221 Jews [58.3%], mean age 14.7 ± 1.9 years); 73.1% had a positive family history of T2D. Mean body mass index (BMI) z-score was 1.96 ± 0.7, higher in Jews than Arabs. High systolic (≥ 130 mmHg) and diastolic blood pressure (≥ 85 mmHg) were observed in 33.7% and 7.8% of patients, respectively; mean glycosylated hemoglobin (A1c) level at diagnosis was 8.8 ± 2.5%. Dyslipidemia, with high triglyceride (>150 mg/dl) and low HDL-c (<40 mg/dl) levels, was found in 45.6% and 56.5%, respectively. Microalbuminuria and retinopathy were documented at diagnosis, 15.2% and 1.9%, respectively) and increased (36.7% and 4.6%, respectively) at follow-up of 2.9 ± 2.1 years. Criteria of metabolic syndrome were met by 224 (62.2%) patients, and fatty liver documented in 65%, mainly Jews. Psychosocial comorbidity was found in 31%. Treatment with metformin (45.6%), insulin (20.6%), and lifestyle modification (18%) improved glycemic control.

CONCLUSION

Youth-onset T2D in Israel has increased significantly and presents a unique profile.

© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Address: Pediatric Diabetes Clinic, Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, Haifa, Israel.; The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.; The Jesse Z and Sara Lea Shafer Institute of Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.; Pediatric Endocrine and Diabetes Unit, Carmel Medical Center, Haifa, Israel.; Pediatric Endocrine Institute, Ha'Emek Medical Center, Afula, Israel.; Pediatric Endocrinology and Diabetes Unit, Soroka Medical Center, Beer Sheva, Israel.; The Faculty of Health Sciences, Goldman School of Medicine, Ben-Gurion University of the Negev, Beer Sheva, Israel.; Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.; National Juvenile Diabetes Center, Maccabi Health Care Services, Ra'anana, Israel.; Division of Pediatric Endocrinology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.; Pediatric Specialist Clinic, Clalit Health Services, Jerusalem, Israel.; Pediatric Endocrinology and Diabetes Unit, Shaare Zedek Medical Center, Jerusalem, Israel.; Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.; Pediatric Endocrine Unit, Department of Pediatrics, Assuta Ashdod Medical Center, Ashdod, Israel.; Pediatric Endocrinology Institute, Shamir Medical Center (Assaf Harofeh), Zerifin, Israel.; Pediatric Endocrinology and Diabetes Unit, Edith Wolfson Medical Center, Holon, Israel.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.